1 years treating Myeloma
350 Myeloma patients anually
clinical research in active and relapsed refractory multiple myeloma disease. I am a principal investigator in clinical trials within the Alliance for Clinical Trials, investigator-initiated and investigator sponsored trials. My area of interest in clinical trials includes use of immunotherapies and targeted therapies, such as bispecific/tri-specific antibodies, antibody-drug conjugates and modern immune modulating drugs (ex. cereblon modulators). Additionally, I’m working on therapeutic advancement of minority populations and enhanced inclusion of these patients in clinical trials to allow for real world representative diversity and true equity in the treatment of all patients with multiple myeloma.